ADPT Adaptive Biotechnologies Corporation Stock Quote

ADPT [NASD]

Adaptive Biotechnologies Corporation

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	1.30%	Shs Outstand	134.37M	Perf Week	7.98%
Market Cap	8.98B	Forward P/E	-	EPS next Y	-1.15	Insider Trans	-84.28%	Shs Float	128.88M	Perf Month	16.21%
Income	-122.30M	PEG	-	EPS next Q	-0.29	Inst Own	78.70%	Short Float	3.57%	Perf Quarter	26.54%
Sales	92.40M	P/S	97.18	EPS this Y	-42.00%	Inst Trans	-2.93%	Short Ratio	5.69	Perf Half Y	63.17%
Book/sh	5.77	P/B	11.28	EPS next Y	-6.50%	ROA	-13.10%	Target Price	62.17	Perf Year	137.82%
Cash/sh	6.05	P/C	10.75	EPS next 5Y	2.20%	ROE	-20.10%	52W Range	15.19 - 66.87	Perf YTD	10.08%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-12.90%	52W High	-2.66%	Beta	-
Dividend %	-	Quick Ratio	8.60	Sales past 5Y	-	Gross Margin	75.90%	52W Low	328.51%	ATR	3.09
Employees	453	Current Ratio	8.70	Sales Q/Q	0.80%	Oper. Margin	-	RSI (14)	66.73	Volatility	4.44% 4.88%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-143.60%	Profit Margin	-	Rel Volume	1.92	Prev Close	65.65
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	Payout	-	Avg Volume	809.11K	Price	65.09
Recom	1.60	SMA20	7.62%	SMA50	20.80%	SMA200	47.46%	Volume	1,551,073	Change	-0.85%

Oct-08-20

Resumed

BTIG Research

Buy

$60

Sep-09-20

Initiated

Morgan Stanley

Equal-Weight

$42

Jun-03-20

Initiated

Goldman

Buy

$60

Jul-23-19

Initiated

BTIG Research

Buy

$46

Jul-22-19

Initiated

William Blair

Outperform

Jul-22-19

Initiated

Guggenheim

Buy

$47

Jul-22-19

Initiated

Goldman

Neutral

$32

Jul-22-19

Initiated

Cowen

Outperform

Jul-22-19

Initiated

BofA/Merrill

Buy

$45

Jan-12-21 08:15AM	The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga
Jan-11-21 04:01PM	Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics GlobeNewswire
Jan-06-21 10:53AM	Billionaire Andreas Halvorsens Top 10 Stock Picks Insider Monkey
Dec-30-20 04:30PM	Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
08:51AM	Do Options Traders Know Something About Adaptive Biotechnologies (ADPT) Stock We Don't? Zacks
Dec-06-20 10:00AM	Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting GlobeNewswire
Nov-23-20 08:00AM	Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients GlobeNewswire
Nov-19-20 06:32AM	5 Under-the-Radar Tickers That Will Stomp the Market in 2021 Motley Fool -6.11%
Nov-13-20 08:00AM	Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections GlobeNewswire
Nov-11-20 05:21AM	Does Adaptive Biotechnologies' (NASDAQ:ADPT) Share Price Gain of 66% Match Its Business Performance? Simply Wall St. +10.33%
05:00AM	Adaptive Biotechnologies Corporation (ADPT) Q3 2020 Earnings Call Transcript Motley Fool
Nov-10-20 05:25PM	Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates Zacks
05:22PM	Recap: Adaptive Biotechnologies Q3 Earnings Benzinga
04:13PM	Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio GlobeNewswire
04:10PM	Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-03-20 12:30PM	Earnings Preview: Adaptive Biotechnologies (ADPT) Q3 Earnings Expected to Decline Zacks +5.19%
Oct-28-20 05:30PM	Amgen Earnings, Sales Top Wall Street Views; Hikes Earnings Guidance Investor's Business Daily
Oct-13-20 04:05PM	Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020 GlobeNewswire
Sep-28-20 10:52AM	Do Hedge Funds Love Adaptive Biotechnologies Corporation (ADPT)? Insider Monkey
Sep-01-20 04:03PM	Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference GlobeNewswire
Aug-11-20 01:01AM	Adaptive Biotechnologies Corporation (ADPT) Q2 2020 Earnings Call Transcript Motley Fool
Aug-10-20 06:35PM	Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results GlobeNewswire
12:44PM	Did Hedge Funds Make The Right Call On Adaptive Biotechnologies Corporation (ADPT)? Insider Monkey
08:05AM	Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit GlobeNewswire
Aug-06-20 09:24AM	Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia GlobeNewswire
Aug-04-20 09:30AM	Adaptive Biotechnologies Launches immunoSEQ T-MAP COVID, First Molecular T Cell Monitoring Tool for SARS-CoV-2 GlobeNewswire
Jul-30-20 06:19AM	Is Adaptive Biotechnologies a Buy? Motley Fool
Jul-28-20 06:04PM	Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease GlobeNewswire
Jul-16-20 12:00PM	Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock? Zacks -8.58%
Jul-15-20 07:47PM	Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jul-14-20 04:44PM	Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-09-20 04:29PM	Here's Why Adaptive Biotechnologies Soared 61.7% in the First Half of 2020 Motley Fool
08:05AM	Adaptive Biotechnologies to Report Second Quarter Financial Results on August 10, 2020 GlobeNewswire
Jun-23-20 11:54AM	Hedge Funds Never Been Less Bullish On Adaptive Biotechnologies Corporation (ADPT) Insider Monkey
Jun-17-20 08:56AM	How Adaptive Biotechnologies (ADPT) Stock Stands Out in a Strong Industry Zacks
Jun-15-20 10:27AM	Microsoft (MSFT) and Adaptive Roll Out ImmuneCODE Database Zacks
Jun-11-20 09:00AM	Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus PR Newswire
Jun-08-20 04:03PM	UPDATE Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences GlobeNewswire
Jun-07-20 06:25AM	Goldman Sachs: These 2 Stocks Are Poised to Surge by at Least 30% TipRanks
May-27-20 04:03PM	Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences GlobeNewswire
May-19-20 08:03AM	5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up Zacks
May-18-20 02:47PM	Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video
May-14-20 11:51AM	Coronavirus Vaccine Progress Accelerates Yahoo Finance
May-13-20 12:31PM	Adaptive Biotechnologies Corporation (ADPT) Q1 2020 Earnings Call Transcript Motley Fool -6.54%
07:02AM	What's Behind Adaptive Biotechnologies' Q1 Earnings Miss Motley Fool
May-12-20 04:03PM	Adaptive Biotechnologies Reports First Quarter 2020 Financial Results GlobeNewswire
08:06AM	The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings Benzinga
May-11-20 10:57AM	Biotech Stock Q1 Earnings Due on May 12: ADPT, VIR, TPTX Zacks +5.77%
09:57AM	Is a Surprise Coming for Adaptive Biotechnologies (ADPT) This Earnings Season? Zacks
May-08-20 09:09AM	Is a Beat in Store for Sunoco (SUN) This Earnings Season? Zacks
May-06-20 03:06PM	Coronavirus update: U.S. death toll tops 71,000, as Trump backs off plan to wind down pandemic task force MarketWatch
02:50PM	These 23 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
12:10PM	Adaptive Biotechnologies and Microsoft Announce New Study of COVID-19 Immune Response Motley Fool
08:19AM	Adaptive, Microsoft to conduct study evaluating T-cells in COVID-19 patients MarketWatch
08:00AM	Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference GlobeNewswire
May-05-20 12:00PM	Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing PR Newswire
Apr-30-20 08:51AM	Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat Zacks
06:39AM	Better Buy: Illumina vs. Adaptive Biotechnologies Motley Fool
Apr-27-20 04:03PM	Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020 GlobeNewswire +10.03%
Apr-20-20 08:15AM	Gilead Increases Enrollment Target, Pharma Rally Continues Zacks +5.58%
Apr-17-20 09:13PM	Adaptive Biotechnologies Collaborations Could Be Vital in Fight Against COVID-19 SmarterAnalyst
12:40PM	4 Healthcare Stocks to Buy For Coronavirus Innovation InvestorPlace
Apr-15-20 04:47PM	Andreas Halvorsen Checks Into Zentalis Pharmaceuticals GuruFocus.com
08:26AM	Pharma Stocks Rally on Sanofi, GSK Coronavirus Vaccine Tie-Up Zacks
Apr-09-20 07:45PM	Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx GlobeNewswire
Apr-07-20 08:35PM	Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration PR Newswire -11.21%
Apr-05-20 10:14AM	With gowns and masks in short supply, researchers test drugs to prevent COVID-19 infections in health care workers MarketWatch
Apr-03-20 10:51AM	Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In Zacks -8.57%
Apr-02-20 07:58PM	Adaptive, Amgen collaborate on development of COVID-19 treatment American City Business Journals
05:50PM	Covid Report: Amgen Pops As Heavyweight Biotech Enters Coronavirus Ring Investor's Business Daily
04:23PM	Biotech Amgen, Adaptive Tech Join Forces on New Coronavirus Drug SmarterAnalyst
04:04PM	Coronavirus update: 1 million global cases, 51,485 deaths and U.S. workers file for benefits in record numbers MarketWatch
12:29PM	Democrats Delay Convention; Italy Infections Slow: Virus Update Bloomberg
09:34AM	Amgen, Adaptive Biotechnologies ink COVID-19 antibody development collaboration MarketWatch
09:00AM	Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19 PR Newswire
Mar-27-20 02:52PM	Hedge Funds Interest Was Stagnant In Adaptive Biotechnologies Corporation (ADPT) Before The Coronavirus Insider Monkey
Mar-24-20 04:45PM	Microsoft, Adaptive partner to better diagnose COVID-19 in research with implications for future pandemics American City Business Journals
Mar-23-20 11:06AM	Microsoft, Adaptive Biotech Collaborate to Fight COVID-19 Zacks
Mar-20-20 02:00PM	Chad Cohen shares his IPO playbook after leading two Seattle companies through theirs American City Business Journals
01:02PM	Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access PR Newswire
Feb-29-20 07:12AM	Here's What Analysts Are Forecasting For Adaptive Biotechnologies Corporation After Its Annual Results Simply Wall St.
Feb-27-20 05:54PM	Adaptive Biotechnologies poised for big growth in 2020 American City Business Journals
Feb-26-20 04:05PM	Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-21-20 10:20AM	MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates Zacks
Feb-19-20 04:05PM	Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference GlobeNewswire +5.57%
Feb-12-20 04:05PM	Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020 GlobeNewswire
Feb-10-20 08:44AM	Why Earnings Season Could Be Great for Adaptive (ADPT) Zacks
Feb-03-20 11:27AM	Andreas Halvorsen Trims Adaptive Biotechnologies Stake GuruFocus.com
Jan-31-20 11:52AM	Insiders Roundup: Texas Instruments, Homolody Medicines GuruFocus.com
Jan-29-20 09:50AM	Thermo Fisher Scientific Could Trade Higher in the Weeks and Months Ahead TheStreet.com
Jan-23-20 08:53PM	Adaptive Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jan-22-20 08:25AM	The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings Benzinga
Jan-21-20 04:39PM	Adaptive Announces Proposed Public Offering of Common Stock GlobeNewswire
04:02PM	Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019 GlobeNewswire
Jan-13-20 07:30AM	Adaptive and Genentech Partner to Use clonoSEQ® Assay to Measure Minimal Residual Disease as a Primary Endpoint in Phase III Study of Chronic Lymphocytic Leukemia Patients GlobeNewswire
Jan-08-20 07:30AM	Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia GlobeNewswire
Dec-30-19 04:05PM	Adaptive Biotechnologies to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
10:04AM	Top Ranked Momentum Stocks to Buy for December 30th Zacks
Dec-26-19 02:47PM	Tech will drive change in health care throughout next decade American City Business Journals

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GRIFFIN MICHELLE RENEE	Director	Jan 14	Option Exercise	7.80	6,000	46,800	6,000	Jan 15 08:00 PM
RUBINSTEIN JULIE	President	Jan 14	Option Exercise	6.32	15,000	94,800	15,000	Jan 15 08:00 PM
GRIFFIN MICHELLE RENEE	Director	Jan 14	Sale	65.88	6,000	395,253	0	Jan 15 08:00 PM
RUBINSTEIN JULIE	President	Jan 14	Sale	65.62	15,000	984,341	0	Jan 15 08:00 PM
Cohen Chad M	Chief Financial Officer	Jan 13	Option Exercise	6.32	50,000	316,000	51,000	Jan 15 05:00 PM
RUBINSTEIN JULIE	President	Jan 13	Option Exercise	6.32	15,000	94,800	15,000	Jan 15 08:00 PM
Cohen Chad M	Chief Financial Officer	Jan 13	Sale	63.41	50,000	3,170,268	1,000	Jan 15 05:00 PM
RUBINSTEIN JULIE	President	Jan 13	Sale	63.22	15,000	948,253	0	Jan 15 08:00 PM
Cohen Chad M	Chief Financial Officer	Jan 12	Option Exercise	6.32	75,000	474,000	76,000	Jan 13 08:00 PM
RUBINSTEIN JULIE	President	Jan 12	Option Exercise	6.32	15,000	94,800	15,000	Jan 13 08:00 PM
Cohen Chad M	Chief Financial Officer	Jan 12	Sale	62.59	75,000	4,694,543	1,000	Jan 13 08:00 PM
RUBINSTEIN JULIE	President	Jan 12	Sale	62.69	15,000	940,281	0	Jan 13 08:00 PM
RUBINSTEIN JULIE	President	Jan 11	Option Exercise	6.32	15,000	94,800	15,000	Jan 13 08:00 PM
RUBINSTEIN JULIE	President	Jan 11	Sale	61.18	15,000	917,679	0	Jan 13 08:00 PM
RUBINSTEIN JULIE	President	Jan 08	Option Exercise	6.32	15,000	94,800	15,000	Jan 11 09:00 PM
RUBINSTEIN JULIE	President	Jan 08	Sale	60.46	8,814	532,895	0	Jan 11 09:00 PM
RUBINSTEIN JULIE	President	Jan 07	Option Exercise	6.32	15,000	94,800	15,000	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 07	Sale	57.30	15,000	859,500	0	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 06	Option Exercise	6.32	15,000	94,800	15,000	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 06	Sale	54.89	15,000	823,377	0	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 05	Option Exercise	6.32	15,000	94,800	15,000	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 05	Sale	55.99	15,000	839,911	0	Jan 07 07:00 PM
RUBINSTEIN JULIE	President	Jan 04	Option Exercise	6.32	15,000	94,800	15,000	Jan 07 07:00 PM
DOBMEIER ERIC	Director	Jan 04	Option Exercise	6.32	10,000	63,200	10,000	Jan 06 08:00 PM
BENZENO SHARON	Chief Business Development Off	Jan 04	Option Exercise	6.72	6,771	45,475	6,771	Jan 06 08:00 PM
RUBINSTEIN JULIE	President	Jan 04	Sale	57.17	15,000	857,476	0	Jan 07 07:00 PM
DOBMEIER ERIC	Director	Jan 04	Sale	57.34	10,000	573,369	0	Jan 06 08:00 PM
BENZENO SHARON	Chief Business Development Off	Jan 04	Sale	57.39	6,771	388,583	0	Jan 06 08:00 PM
Taylor Stacy L	SVP and General Counsel	Dec 31	Option Exercise	7.46	6,530	48,720	7,830	Dec 31 09:00 PM
RUBINSTEIN JULIE	President	Dec 31	Option Exercise	6.32	15,000	94,800	15,000	Dec 31 09:00 PM
Taylor Stacy L	SVP and General Counsel	Dec 31	Sale	57.86	6,530	377,797	1,300	Dec 31 09:00 PM
RUBINSTEIN JULIE	President	Dec 31	Sale	57.93	15,000	868,897	0	Dec 31 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 30	Option Exercise	0.33	16,520	5,452	1,794,700	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 30	Option Exercise	6.32	15,000	94,800	15,000	Dec 30 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 30	Sale	59.44	16,520	981,975	1,778,180	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 30	Sale	59.61	15,000	894,219	0	Dec 30 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 29	Option Exercise	0.33	16,790	5,541	1,794,970	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 29	Option Exercise	6.32	15,000	94,800	15,000	Dec 30 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 29	Sale	59.28	16,790	995,348	1,778,180	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 29	Sale	60.28	15,000	904,193	0	Dec 30 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 28	Option Exercise	0.33	16,250	5,363	1,794,430	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 28	Option Exercise	6.32	15,000	94,800	15,000	Dec 30 09:00 PM
ROBINS CHAD M	CEO and Chairman	Dec 28	Sale	60.95	16,250	990,496	1,778,180	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 28	Sale	61.58	15,000	923,767	0	Dec 30 09:00 PM
RUBINSTEIN JULIE	President	Dec 24	Option Exercise	6.32	15,000	94,800	15,000	Dec 28 07:00 PM
RUBINSTEIN JULIE	President	Dec 24	Sale	63.53	15,000	953,015	0	Dec 28 07:00 PM
RUBINSTEIN JULIE	President	Dec 23	Option Exercise	6.32	15,000	94,800	15,000	Dec 23 07:00 PM
RUBINSTEIN JULIE	President	Dec 23	Sale	64.26	15,000	963,853	0	Dec 23 07:00 PM
HILL NANCY LOUISE	EVP, Operations & Program Mana	Dec 22	Option Exercise	0.84	57,000	47,880	67,000	Dec 23 07:00 PM
RUBINSTEIN JULIE	President	Dec 22	Option Exercise	6.32	15,000	94,800	15,000	Dec 23 07:00 PM
HILL NANCY LOUISE	EVP, Operations & Program Mana	Dec 22	Sale	63.71	57,000	3,631,702	10,000	Dec 23 07:00 PM
RUBINSTEIN JULIE	President	Dec 22	Sale	63.71	15,000	955,706	0	Dec 23 07:00 PM
Pellini Michael J	Director	Dec 21	Option Exercise	6.55	25,000	163,750	25,000	Dec 23 07:00 PM
BENZENO SHARON	Chief Business Development Off	Dec 21	Option Exercise	6.27	417	2,615	417	Dec 23 07:00 PM
RUBINSTEIN JULIE	President	Dec 21	Option Exercise	6.32	15,000	94,800	15,000	Dec 23 07:00 PM
Pellini Michael J	Director	Dec 21	Sale	60.00	25,000	1,500,000	0	Dec 23 07:00 PM
BENZENO SHARON	Chief Business Development Off	Dec 21	Sale	59.14	417	24,661	0	Dec 23 07:00 PM
RUBINSTEIN JULIE	President	Dec 21	Sale	59.43	15,000	891,424	0	Dec 23 07:00 PM
HERSHBERG ROBERT	Director	Dec 15	Option Exercise	0.45	2,000	900	2,000	Dec 16 09:00 PM
LO FRANCIS	Chief People Officer	Dec 15	Option Exercise	7.80	2,000	15,600	2,000	Dec 16 09:00 PM
HERSHBERG ROBERT	Director	Dec 15	Sale	55.93	2,000	111,856	0	Dec 16 09:00 PM
LO FRANCIS	Chief People Officer	Dec 15	Sale	55.94	2,000	111,874	0	Dec 16 09:00 PM
HILL NANCY LOUISE	EVP, Operations & Program Mana	Dec 14	Option Exercise	0.84	40,000	33,600	50,000	Dec 16 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Dec 14	Option Exercise	7.80	6,000	46,800	6,000	Dec 16 09:00 PM
HILL NANCY LOUISE	EVP, Operations & Program Mana	Dec 14	Sale	59.00	40,000	2,360,000	10,000	Dec 16 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Dec 14	Sale	58.84	6,000	353,040	0	Dec 16 09:00 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Dec 14	Sale	55.65	1,000,000	55,650,000	29,993,708	Dec 16 09:03 PM
SANG CHARLES	SVP, External Affairs	Dec 11	Option Exercise	6.55	50,000	327,500	50,000	Dec 11 09:00 PM
SANG CHARLES	SVP, External Affairs	Dec 11	Sale	56.13	50,000	2,806,500	0	Dec 11 09:00 PM
BOBULSKY SUSAN	SVP, Diagnostics, clonoSEQ	Dec 10	Option Exercise	1.98	25,000	49,500	25,000	Dec 11 09:00 PM
BOBULSKY SUSAN	SVP, Diagnostics, clonoSEQ	Dec 10	Sale	55.00	25,000	1,375,000	0	Dec 11 09:00 PM
Cohen Chad M	Chief Financial Officer	Dec 08	Option Exercise	6.32	30,000	189,600	31,000	Dec 09 07:05 PM
Cohen Chad M	Chief Financial Officer	Dec 08	Sale	51.24	30,000	1,537,238	1,000	Dec 09 07:05 PM
BALDO LANCE	Chief Medical Officer	Dec 07	Option Exercise	7.80	6,250	48,750	6,250	Dec 09 07:05 PM
BALDO LANCE	Chief Medical Officer	Dec 07	Sale	50.41	6,250	315,088	0	Dec 09 07:05 PM
BENZENO SHARON	Chief Business Development Off	Dec 01	Option Exercise	6.72	6,770	45,468	6,770	Dec 02 08:00 PM
BENZENO SHARON	Chief Business Development Off	Dec 01	Sale	48.87	6,770	330,856	0	Dec 02 08:00 PM
Taylor Stacy L	SVP and General Counsel	Nov 23	Option Exercise	7.03	2,880	20,250	4,180	Nov 24 08:00 PM
Taylor Stacy L	SVP and General Counsel	Nov 23	Sale	46.31	2,880	133,359	1,300	Nov 24 08:00 PM
ROBINS CHAD M	CEO and Chairman	Nov 19	Option Exercise	0.33	16,680	5,504	1,794,860	Nov 19 09:00 PM
BENZENO SHARON	Chief Business Development Off	Nov 19	Option Exercise	6.27	416	2,608	416	Nov 23 06:05 AM
ROBINS CHAD M	CEO and Chairman	Nov 19	Sale	46.57	16,680	776,741	1,778,180	Nov 19 09:00 PM
BENZENO SHARON	Chief Business Development Off	Nov 19	Sale	48.86	416	20,326	0	Nov 23 06:05 AM
ROBINS CHAD M	CEO and Chairman	Nov 18	Option Exercise	0.33	16,680	5,504	1,794,860	Nov 19 09:00 PM
ROBINS CHAD M	CEO and Chairman	Nov 18	Sale	48.28	16,680	805,346	1,778,180	Nov 19 09:00 PM
ROBINS CHAD M	CEO and Chairman	Nov 17	Option Exercise	0.33	16,680	5,504	1,794,860	Nov 19 09:00 PM
ROBINS CHAD M	CEO and Chairman	Nov 17	Sale	46.12	16,680	769,343	1,778,180	Nov 19 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Nov 16	Option Exercise	7.80	6,000	46,800	6,000	Nov 18 09:00 PM
HERSHBERG ROBERT	Director	Nov 16	Option Exercise	0.45	2,000	900	2,000	Nov 18 09:00 PM
LO FRANCIS	Chief People Officer	Nov 16	Option Exercise	7.80	2,000	15,600	2,000	Nov 18 09:00 PM
GRIFFIN MICHELLE RENEE	Director	Nov 16	Sale	47.69	6,000	286,135	0	Nov 18 09:00 PM
HERSHBERG ROBERT	Director	Nov 16	Sale	47.69	2,000	95,381	0	Nov 18 09:00 PM
LO FRANCIS	Chief People Officer	Nov 16	Sale	47.68	2,000	95,351	0	Nov 18 09:00 PM
VIKING GLOBAL PERFORMANCE LLC	10% Owner	Nov 11	Sale	49.52	2,500,000	123,787,500	30,993,708	Nov 13 09:00 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Nov 11	Sale	49.52	2,500,000	123,787,500	30,993,708	Nov 13 09:01 PM
Cohen Chad M	Chief Financial Officer	Nov 09	Option Exercise	6.32	30,000	189,600	31,000	Nov 12 09:00 PM
Cohen Chad M	Chief Financial Officer	Nov 09	Sale	49.16	30,000	1,474,705	1,000	Nov 12 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Nov 06	Option Exercise	6.32	11,100	70,152	11,779	Nov 06 09:00 PM
BALDO LANCE	Chief Medical Officer	Nov 06	Option Exercise	7.80	6,250	48,750	6,250	Nov 10 09:00 PM
ROBINS HARLAN S	Chief Scientific Officer	Nov 06	Sale	51.50	11,100	571,629	679	Nov 06 09:00 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience